mRCC Control Seen After Immunotherapy Is Stopped – Clinical Oncology News
|
mRCC Control Seen After Immunotherapy Is Stopped
Clinical Oncology News mRCC Control Seen After Immunotherapy Is Stopped. Orlando, Fla.—Patients with mRCC who respond to programmed death 1/programmed death ligand 1 checkpoint inhibitor therapy can have persistent clinical benefit, even after treatment discontinuation. |
|
Urothelial Ca immunotherapy approved for first-line use
ModernMedicine The regulatory agency’s decision makes atezolizumab the only cancer immunotherapy agent approved for initial treatment of urothelial carcinoma in patients who are ineligible for cisplatin. In May 2016, atezolizumab became the first immunotherapy agent … |
Bloomberg |
Companies Racing to Use Crispr to Fight Disease
Bloomberg Crispr is a new gene-editing tool that could transform biotechnology. Bloomberg’s Doni Bloomfield spoke with the three public companies located in Cambridge, Massachusetts that are racing to use Crispr in people. (Source: Bloomberg) … |
Technology Networks |
Oxford Genetics Licenses CRISPR IP From ERS Genomics
GenomeWeb “Licensing the CRISPR gene-editing technology from ERS Genomics is another step on our journey to establishing the most efficient and integrated service portfolio in this sector,” Oxford Genetics CCO Paul Brooks said in a statement. “We are excited to … Oxford Genetics Licenses CRISPR Gene Editing Technology from ERS GenomicsPharmaceutical Technology Magazine (press release) (blog) |